Pan Junwei
Department of Pharmacy , Deqing Hospital of Traditional Chinese Medicine, No.383 Qunyi Street, Wukang Town, Deqing County, Huzhou, 313200, Zhejiang, China.
Sci Rep. 2025 Jul 2;15(1):23496. doi: 10.1038/s41598-025-09206-5.
The study aims to explore the key mechanism of Gancao Renshen Zhixue Decoction (GCRSZXD) in treating liver cirrhosis (LC). Common targets of GCRSZXD and LC were obtained, and the hub genes were identified by network construction and differential expression analysis. Key active ingredients were determined by intersecting the top 10 common target-related and hub gene-related active ingredients. Then, enrichment analysis was performed to identify the essential pathways. Besides, the GCRSZXD-Chinese herb-active ingredient-hub gene-signaling pathway-LC network was constructed to explore potential regulatory mechanisms. Molecular docking and molecular dynamic simulation were used to verify the binding ability of key active ingredients with hub genes. Finally, hub gene expression was validated in vitro. Totally 180 common targets and 120 associated active ingredients were identified. Three hub genes, AKT1, EGFR, and SRC were differentially expressed in LC and healthy groups (P < 0.05). Five key active ingredients and three signaling pathways were obtained. Excellent binding effects of receptors and ligands were observed. Additionally, GCRSZXD significantly reduced the expression of AKT1, EGFR, and SRC in the TGF-β1-induced cells. In conclusion, this study reveals the mechanism of GCRSZXD in LC treatment, which provides the theoretical basis for the mechanism research of GCRSZXD.
本研究旨在探讨甘草人参止血汤（GCRSZXD）治疗肝硬化（LC）的关键机制。获取GCRSZXD和LC的共同靶点，并通过网络构建和差异表达分析鉴定枢纽基因。通过交叉前10个与共同靶点相关和与枢纽基因相关的活性成分来确定关键活性成分。然后，进行富集分析以确定关键通路。此外，构建GCRSZXD-中药-活性成分-枢纽基因-信号通路-LC网络以探索潜在的调控机制。采用分子对接和分子动力学模拟验证关键活性成分与枢纽基因的结合能力。最后，在体外验证枢纽基因的表达。共鉴定出180个共同靶点和120种相关活性成分。三个枢纽基因AKT1、EGFR和SRC在LC组和健康组中差异表达（P < 0.05）。获得了五种关键活性成分和三条信号通路。观察到受体和配体具有良好的结合效果。此外，GCRSZXD显著降低了TGF-β1诱导细胞中AKT1、EGFR和SRC的表达。总之，本研究揭示了GCRSZXD治疗LC的机制，为GCRSZXD的机制研究提供了理论依据。
